SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $346.66 million. The enterprise value is $249.16 million.
| Market Cap | 346.66M |
| Enterprise Value | 249.16M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 90.99 million shares outstanding. The number of shares has increased by 417.54% in one year.
| Current Share Class | 90.99M |
| Shares Outstanding | 90.99M |
| Shares Change (YoY) | +417.54% |
| Shares Change (QoQ) | +48.91% |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 42.66% |
| Float | 59.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.48 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.22, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.22 |
| Quick Ratio | 8.93 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -310.04 |
Financial Efficiency
Return on equity (ROE) is -11.27% and return on invested capital (ROIC) is -37.67%.
| Return on Equity (ROE) | -11.27% |
| Return on Assets (ROA) | -33.46% |
| Return on Invested Capital (ROIC) | -37.67% |
| Return on Capital Employed (ROCE) | -31.71% |
| Weighted Average Cost of Capital (WACC) | 7.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$253,346 |
| Employee Count | 86 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.75% in the last 52 weeks. The beta is 0.53, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +71.75% |
| 50-Day Moving Average | 3.75 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 52.31 |
| Average Volume (20 Days) | 392,605 |
Short Selling Information
The latest short interest is 4.66 million, so 5.12% of the outstanding shares have been sold short.
| Short Interest | 4.66M |
| Short Previous Month | 4.38M |
| Short % of Shares Out | 5.12% |
| Short % of Float | 7.79% |
| Short Ratio (days to cover) | 9.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | -48.27M |
| Operating Income | -71.82M |
| Pretax Income | -12.78M |
| Net Income | -21.79M |
| EBITDA | -68.71M |
| EBIT | -71.82M |
| Earnings Per Share (EPS) | -$1.56 |
Balance Sheet
The company has $102.63 million in cash and $5.13 million in debt, with a net cash position of $97.50 million or $1.07 per share.
| Cash & Cash Equivalents | 102.63M |
| Total Debt | 5.13M |
| Net Cash | 97.50M |
| Net Cash Per Share | $1.07 |
| Equity (Book Value) | 214.79M |
| Book Value Per Share | 2.57 |
| Working Capital | 96.23M |
Cash Flow
In the last 12 months, operating cash flow was -$53.94 million and capital expenditures -$3.50 million, giving a free cash flow of -$57.44 million.
| Operating Cash Flow | -53.94M |
| Capital Expenditures | -3.50M |
| Depreciation & Amortization | 3.12M |
| Net Borrowing | -148,412 |
| Free Cash Flow | -57.44M |
| FCF Per Share | -$0.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -417.54% |
| Shareholder Yield | -417.54% |
| Earnings Yield | -6.29% |
| FCF Yield | -16.57% |
Analyst Forecast
The average price target for SABS is $11.64, which is 205.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.64 |
| Price Target Difference | 205.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |